Results 171 to 180 of about 14,491 (226)

Postoperative adjuvant therapy for driver gene-positive non-small-cell lung cancer patients. [PDF]

Chin Med J (Engl)
Lung Cancer Treatment Collaboration Group, Chinese Medical Association.   +1 more
europepmc   +1 more source

A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer. [PDF]

Curr Oncol
Khan SR, Kotrri E, Breadner D, Kundapur V, Manna M.   +4 more
europepmc   +1 more source

A case report and literature review of a pathologic complete response to alectinib in <i>ALK</i>-positive stage IV non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Janson M, Curcio H, Le Rochais JP, Planchard G, Demontrond P, Gervais R.   +5 more
europepmc   +1 more source

Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report. [PDF]

Thorac Cancer
Ozaki M, Ikushima H, Suzuki M, Yokoyama A, Fukuda K, Watanabe K, Shinozaki-Ushiku A, Kato M, Ushiku T, Aburatani H, Oda K, Kage H.   +11 more
europepmc   +1 more source

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLC. [PDF]

JTO Clin Res Rep
Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA.   +12 more
europepmc   +1 more source

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival? [PDF]

Transl Lung Cancer Res
Ulhøi MP, Meldgaard P.
europepmc   +1 more source

Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review. [PDF]

Oncol Lett
Qiu X, Wei Y, Wang X, Xu S, Zhang Y, He H, Zhou X.   +6 more
europepmc   +1 more source

Body weight gain associated with alectinib in patients with ALK+ non-small cell lung cancer: pooled analysis of individual patient data from 4 prospective clinical trials [PDF]

Baart, Sara, Dingemans, Anne-Marie, Mathijssen, Ron, Paats, Marthe, Schols, Annemie M.W.J., Sikkema, Barend, Smit, Egbert, van Rossum, Liesbeth   +7 more
core  

Some of the next articles are maybe not open access.

Related searches:

Alectinib

Reactions Weekly, 2018
Alectinib is an ATP-competitive small molecule and a second-generation inhibitor of ALK. EML4-ALK rearrangement is found in 3-5% of patients with NSCLC. The first-generation inhibitor crizotinib has changed the treatment dramatically, though most of the patients show disease progression within one year.
Herden, Marie, Waller, Cornelius
  +8 more sources

Alectinib

Reactions Weekly
  +17 more sources